বাংলায় দেখুন
Linzolid

Linzolid

Tablet

🧬 Linezolid 🏢 Incepta Pharmaceuticals Ltd.
Generic Name Linezolid
Manufacturer Incepta Pharmaceuticals Ltd.
Unit Price Unit Price: ৳ 85.00 (2 x 10: ৳ 1,700.00) Strip Price: ৳ 850.00
Unit Price: ৳ 85.00 (2 x 10: ৳ 1,700.00) Strip Price: ৳ 850.00 ✅ In Stock per unit · Bangladesh
🛒 Buy Now

🔒 Secure checkout  ·  Return & Refund Policy

🔹 Indications

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Pharmacology

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Dosage & Administration

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Interaction

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Contraindications

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Side Effects

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Pregnancy & Lactation

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Precautions & Warnings

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

💡 Frequently Asked Questions

Linzolid is indicated for the treatment of: Nosocomial pneumonia Community-acquired pneumonia Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis Uncomplicated skin and skin structure i...
Linzolid is indicated for the treatment of: Nosocomial pneumonia Community-acquired pneumonia Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis Uncomplicated skin and skin structure i...
Linzolid is indicated for the treatment of: Nosocomial pneumonia Community-acquired pneumonia Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis Uncomplicated skin and skin structure i...

User Reviews

⭐
No reviews yet!
Be the first to share your experience.

Write a Review